13 completed. 13 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 13 |
| Phase 2 | 2 | Completed 2 |
Follow SOC: new trials by email Literature Review of SOC trials Research Report on SOC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19. P1101 (Ropeginterferon alfa-2b), SOC - COVID-19 | Phase 3 | Completed | National Taiwan University Hospital | 134 | 2022-04-01 | 2024-04-16 |
| EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19 BEVA+SOC, SOC - Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome) | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 96 | 2021-04-17 | 2022-12-28 |
| Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1) Liposomal Cyclosporine A, standard of care - Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant | Phase 3 | Completed | Zambon SpA | 62 | 2019-03-26 | 2025-10-27 |
| Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2) Liposomal Cyclosporine A, Standard of Care - Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant | Phase 3 | Completed | Zambon SpA | 169 | 2019-03-26 | 2026-02-10 |
| Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS Ryanodex and Standard of Care, Standard of Care - Exertional Heat Stroke | Phase 3 | Completed | Eagle Pharmaceuticals, Inc. | 17 | 2018-08-19 | 2021-05-19 |
| Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS) TED, SOC, Syringe - Short Bowel Syndrome | Phase 3 | Completed | Shire | 61 | 2017-01-09 | 2025-03-28 |
| Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study Teduglutide, SOC - Short Bowel Syndrome | Phase 3 | Completed | Shire | 29 | 2016-12-09 | 2025-03-19 |
| ODYSSEY (PENTA 20) Dolutegravir, Standard of Care - HIV Infection | Phase 2 / Phase 3 | Completed | PENTA Foundation | 792 | 2016-09-20 | 2025-07-29 |
| Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children DTG +DRV/r, SOC - HIV Infection | Phase 2 / Phase 3 | Completed | PENTA Foundation | 318 | 2016-06-01 | 2021-03-30 |
| Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control Mepolizumab, Placebo, SOC - Asthma | Phase 3 | Completed | GlaxoSmithKline | 556 | 2014-12-11 | 2018-08-06 |
| A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Mepolizumab, SOC - Asthma | Phase 3 | Completed | GlaxoSmithKline | 339 | 2014-05-29 | 2019-12-03 |
| A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002) MK-6072, MK-3415A, Placebo - Clostridium Difficile Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1203 | 2012-02-01 | 2018-09-05 |
| A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001) MK-3415, MK-6072, MK-3415A - Clostridium Difficile Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1452 | 2011-10-10 | 2018-09-05 |
Asthma (2) · Bronchiolitis Obliterans (2) · Clostridium Infections (2) · HIV Infections (2) · Pulmonary Eosinophilia (2) · Rejection, Psychology (2) · Short Bowel Syndrome (2) · COVID-19 (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Hypoxia (1) · Nidovirales Infections (1) · RNA Virus Infections (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1)
GlaxoSmithKline (2) · Merck Sharp & Dohme LLC (2) · PENTA Foundation (2) · Shire (2) · Zambon SpA (2) · Assistance Publique - Hôpitaux de Paris (1) · Eagle Pharmaceuticals, Inc. (1) · National Taiwan University Hospital (1)
United Kingdom (8) · France (6) · Spain (6) · United States (6) · Belgium (5) · Germany (5) · Argentina (3) · Canada (3) · Italy (3) · Ukraine (3) · Czechia (2) · Israel (2) · Netherlands (2) · Portugal (2) · Russia (2)
Paola Castellani, MD (2) · Adrian Hepner (1) · Diana Gibb (1)
PMID 28121498, PMID 29538686, PMID 29788418, PMID 30060024, PMID 30227108, PMID 30455246, PMID 30460321, PMID 31411386, PMID 31628838, PMID 32099847, PMID 32376702, PMID 32504314, PMID 36661328, PMID 38873891, PMID 41858082, PMID 27316794, PMID 28395936, PMID 29949045, PMID 31047111, PMID 31251094, PMID 31507641, PMID 31846705, PMID 31883370, PMID 32101275, PMID 32763217, PMID 33446115, PMID 33848093, PMID 34098955, PMID 34158028, PMID 34817414, PMID 34965338, PMID 35868341, PMID 36055295, PMID 36906440, PMID 37304494, PMID 37766505, PMID 39978387, PMID 41579881
2014 (2), 2016 (2), 2018 (2)